Is the policy being changed because there are now two possible cases of transfusion-transmitted vCJD in the U.K.?
We will be examining the impact of the news coming out of the U.K. and consulting with experts to determine if any changes need to be made to our policy. One should remember that we introduced our current vCJD deferral at a time when transmission of vCJD was considered a theoretical risk. This precautionary policy now appears to have been warranted. If needed we will continue to take measures to add protection to the blood system from vCJD. Any policy change will have to balance the risk of transfusion-transmitted vCJD versus a real risk of supply shortages.
Related Questions
- Is it possible to exclude from the delete policy some special custom tables not present in the original database schema?
- Should the vCJD policy be changed in wake of the new revelations in the U.K. concerning plasma products?
- Is it possible to speed-up the visa requirement formalities in emergency cases?
